Abstract: The present invention relates to a method for preparing 2-substituted 4-hydroxy-4-methyltetrahydropyrans from starting materials comprising at least one 2-alkyl-4,4-dimethyl-1,3-dioxane.

Abstract: Compounds that function, alone or in combination, as inhibitors of pigmentation for the improvement of mammalian skin are described herein. Specifically, the compounds of the present disclosure, namely chiral, non-racemic compounds, function as pigment formation inhibitors thereof to beautify skin and discourage the production of melanins. One or more products, consumer and otherwise, comprising the chiral, non-racemic compounds are disclosed herein. Methods of employing both the compounds of the present disclosure and the products incorporating the present compounds are also disclosed herein.

Abstract: The invention relates to a method for producing 2-substituted 4-hydroxy-4-methyltetrahydropyrans.

Abstract: Compounds that function, alone or in combination, as inhibitors of pigmentation for the improvement of mammalian skin are described herein. Specifically, the compounds of the present disclosure, namely chiral, non-racemic compounds, function as pigment formation inhibitors thereof to beautify skin and discourage the production of melanins. One or more products, consumer and otherwise, comprising the chiral, non-racemic compounds are disclosed herein. Methods of employing both the compounds of the present disclosure and the products incorporating the present compounds are also disclosed herein.

Abstract: A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

Abstract: The present invention provides catalysts, methods, and reactor systems for converting oxygenated hydrocarbons to oxygenated compounds. The invention includes methods for producing cyclic ethers, monooxygenates, dioxygenates, ketones, aldehydes, carboxylic acids, and alcohols from oxygenated hydrocarbons, such as carbohydrates, sugars, sugar alcohols, sugar degradation products, and the like, using catalysts containing palladium, molybdenum, tin, and tungsten. The oxygenated compounds produced are useful in the production of liquid fuels, chemicals, and other products.

Abstract: A secondary battery includes: a cathode; an anode; and non-aqueous electrolytic solution including a cyclic ether compound that includes a skeleton and one or more substituent groups introduced into the skeleton. The skeleton includes one or more four-or-more-membered oxygen-containing rings. The one or more substituent groups each are a monovalent group represented by Formula (1). —X—O—R??(1) (X is one of a divalent chain saturated hydrocarbon group, a halide group thereof, and nothing. R is one of a monovalent chain saturated hydrocarbon group, etc. At least one of one or more Rs includes one or more of the monovalent chain unsaturated hydrocarbon group, the monovalent cyclic unsaturated hydrocarbon group, the monovalent oxygen-containing cyclic unsaturated hydrocarbon group, the halide group thereof, and the monovalent group obtained by bonding two or more thereof, and includes a carbon-carbon multiple bond (one of —C?C— and —C?C—) bonded to an ether bond (—O—).

Abstract: The present invention relates to a polymerizable liquid crystal compound, a liquid crystal composition including the same, and an optically anisotropic body. The polymerizable liquid crystal compound according to the present invention has not only large solubility in various solvents but also high birefringence and excellent coating orientation, and thus it can provide an optically anisotropic body which is thin but superior in optical properties.

Abstract: Disclosed is a method for producing a compound having an amino group and/or a hydroxyl group from a substrate compound having an atomic group containing CO or CS by eliminating such atomic group. The substrate compound, having an atomic group containing CO or CS (for example, an amide, a carbamate, or the like), is allowed to react with a compound expressed by formula (I) below, at a temperature of 120° C. or lower, preferably in the presence of an ammonium salt, to eliminate such atomic group containing CO or CS. In formula (I) A may not be present, and in a case where A is present, A represents an alkyl group having 1 to 6 carbon atoms. H2N-A—NH2 (I) - - -.

Abstract: A compound of formula (I), wherein R1 is hydrogen or a hydroxyl protecting group; and R2 and R3 are same or different and are independently selected from halogen or —O—SO2—X; wherein X is —C1-C4 alkyl; C1-C4 alkyl substituted with one or more halogen; or substituted or unsubstituted phenyl wherein said phenyl substituent is selected from halogen, nitro and C1-C4 alkyl; provided that when R3 is bromine, X is not p-toluoyl; and a process for the preparation thereof.

Abstract: Described is a reagent that enhances acid generation of a photoacid generator and a composition containing such a reagent.

Abstract: Compounds of the formula (I), (Ia) or (Ib) wherein A1, and A? is for example (II) is 1 or 2; X is C1-C4 alkylene or CO; Y is for example O, O(CO), O(CO)O, R1 is for example hydrogen, d-dsalkyl, C3-C30cycloalkyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or C3-C20heteroaryl, all of which optionally are substituted; R2 and R3 for example are C1-C10haloalkylene which is optionally substituted, or R2 and R3 are phenylene, which optionally is substituted; R4 is a group (A) or a group (B); R5 and R6 for example are C1-C20alkyl; or R4 and R5 or R4 and R6 together form a straight-chain C2-C6alkylene, R5 and R6 together form a straight-chain C2-C6alkylene; R7, R8, R9 and R10 ifor example are C1-C20alkyl; M for example is C1-C20alkylene, C2-C20alkenylene, C2-C20alkynylene; R25 and R26 are for example hydrogen, C1-C20alkyl; R27, R28, R29, R30 and R31 are for example hydrogen, C1-C20alkyl, C2-C20alkenyl, C3-C20cycloalkyl, or two radicals R27 and R28, R28 and R29, R29 and R30 and/or R30 and R31 toget

Abstract: The invention provides methods for the identification of small molecules that inhibit MUC1 oligomerization, and the functions flowing therefrom. In addition, small molecules that prevent MUC1 oligomerization are disclosed. Identified molecules will find use in treating a variety of MUC1-related inflammatory conditions, including MUC1-related cancers.

Abstract: A fluorinated monomer of cyclic acetal structure has formula (1) wherein R is a C1-C20 alkyl group which may be substituted with halogen or separated by oxygen or carbonyl, and Z is a divalent organic group which forms a ring with alkylenoxy and contains a polymerizable unsaturated group. A polymer derived from the fluorinated monomer may be endowed with appropriate water repellency, water sliding property, lipophilicity, acid lability and hydrolyzability and is useful in formulating a protective coating composition and a resist composition.

Abstract: There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): wherein Ra represents an alkyl group, such as a C1-16 alkyl group, and preferably an isopropyl group; Rb represents an aryl group, preferably a 4-fluorophenyl group; Rc represents hydrogen, a protecting group or an alkyl group, such as a C1-16 alkyl group, and preferably a methyl group; and Rd represents hydrogen, a protecting group or a SO2Re group where Re is an alkyl group, such as a C1-16 alkyl group, and preferably a methyl group.

Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Abstract: A hydrofluoroether compound comprises at least one five- or six-membered, perfluorinated heterocyclic ring, each ring comprising four or five ring carbon atoms and one or two catenated heteroatoms selected from divalent ether oxygen atoms and trivalent nitrogen atoms, at least one of the catenated heteroatoms being a divalent ether oxygen atom, and each of the ring carbon atoms adjacent to the divalent ether oxygen atom bearing a fluorochemical group that comprises a tetrafluoroethylidene moiety (—(CF3)CF—) that is directly bonded to the ring carbon atom, the fluorochemical group optionally comprising at least one catenated heteroatom selected from divalent ether oxygen atoms and trivalent nitrogen atoms.

Abstract: The present invention relates to a process for the integrated preparation of 2-substituted 4-hydroxy-4-methyltetrahydropyrans and of 2-substituted 4-methyltetrahydropyrans.

Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, rings A and B, Z1, L1, L2, a and b have the meanings indicated in Claim 1, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, IPS or PS-IPS effect.

Abstract: Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same are disclosed. Formulations which include various embodiments of the mesogen-containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed.

Abstract: The present invention relates to compounds represented by the following Formula Ic, in which R2-R6 can each independently be selected from hydrogen or hydrocarbyl (e.g., methyl); L1 and L4 are each independently a divalent linking group, such as a bond or —OC(O)—R8—C(O)O—, where R8 can be divalent hydrocarbyl (e.g., —CH2CH2—); each L2 and each L5 each independently represent a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 and each L6 each independently represent a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t and s are each independently from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; q and r are each independently from 0 to 4 for each s, provided that the sum of q and r is at least 1 for each s; and E1 and E2 can each independently be hydrogen or hydrocarbyl.

Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (polymer stabilized) or PSA (polymer sustained alignment) type.

Abstract: A method of producing honokiol and analogues thereof, and novel intermediates prepared by virtue thereof are disclosed herein. A pharmaceutical composition for treating Parkinson's disease, which contains honokiol and/or the analogues thereof, is also disclosed herein.

Abstract: The invention provides a liquid crystal compound having stability to heat, light and so forth, a wide temperature range of a nematic phase, a small viscosity, a suitable optical anisotropy, a suitable elastic constant K33, a suitable and negative dielectric anisotropy, and an excellent compatibility with other liquid crystal compounds. The invention provides a liquid crystal composition containing the compound described above and having stability to heat, light and so forth, a small viscosity, a suitable optical anisotropy, a suitable and negative dielectric anisotropy, a suitable elastic constant K33, a low threshold voltage, a high maximum temperature of a nematic phase, and a low minimum temperature of the nematic phase. The invention also provides a liquid crystal display device having a short response time, a small power consumption, a low driving voltage, and a large contrast, and containing the composition described above which can be used in a large temperature range.

Abstract: To provide a liquid crystal compound having a large negative value of dielectric anisotropy (As). A compound is represented by formula (1): wherein, in formula (1), one of Y1 and Y2 is fluorine, and the other is CF2H or CF3; G is a ring represented by formula (pr-1) or formula (pr-2): wherein A1 to A3 are independently 1,4-cyclohexylene or 1,4-phenylene; Ra and Rb are independently hydrogen, alkyl having 1 to 20 carbons, or the like; Z0, and Z1 to Z3 are independently a single bond, —(CH2)2—, —CH?CH—, —CF2O—, —OCF2—, —CH2O—, —OCH2—, —COO— or —OCO—; j, m and n are an integer from 0 to 2, and a sum of j, m and n is 0, 1 or 2, however, when m is 0, Y1 is CF2H or CF3, Y2 is fluorine, and Z0 is a single bond, G is a ring represented by formula (pr-1).

Abstract: To provide a liquid crystal compound having a large positive value of dielectric anisotropy and a small viscosity. The compound is represented by formula (1): wherein, in formula (1), R1 is alkyl having 1 to 20 carbons or the like; ring A1 is 1,4-cyclohexylene or the like; ring A2 is 1,4-phenylene, 2-fluoro-1,4-phenylene, 2,6-difluoro-1,4-phenylene or the like; ring A3 is 1,4-cyclohexylene, 1,4-phenylene, 2-fluoro-1,4-phenylene, 2,6-difluoro-1,4-phenylene or the like; and X1 is halogen, alkyl having 1 to 10 carbons or the like, and in the alkyl, at least one of hydrogen may be replaced by halogen.

Abstract: The present invention provides a scalable process for the preparation of stilbenes by (i) condensing 3,5-dialkylbenzyl phosphonates with 4?-O-tetrahydropyranyl benzaldehyde to get 3,5-alkyl-4?-O-tetrahydropyranyl Stilbene and (ii) deprotecting the obtained 3,5-Dialkyl-4?-O-tetrahydropyranylstilbene to yield stilbenes. The present invention also provides a novel intermediate 3,5-Dialkyl-4?-O-tetrahydropyranyl stilbene, which is a key intermediate for the synthesis of stilbenes such as Pterostilbene and Resveratrol. The present invention also provides characteristics of various solid forms of Pterostilbene, methods for their preparation, as well as dosage forms containing the same for administration to or consumption by humans.

Abstract: There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): wherein Ra represents an alkyl group, such as a C1-16 alkyl group, and preferably an isopropyl group; Rb represents an aryl group, preferably a 4-fluorophenyl group; Rc represents hydrogen, a protecting group or an alkyl group, such as a C1-16 alkyl group, and preferably a methyl group; and Rd represents hydrogen, a protecting group or a SO2Re group where Re is an alkyl group, such as a C1-16 alkyl group, and preferably a methyl group.

Abstract: A compound of formula (I), wherein R1 is hydrogen or a hydroxyl protecting group; and R2 and R3 are same or different and are independently selected from halogen or —O—SO2—X; wherein X is —C1-C4 alkyl; C1-C4 alkyl substituted with one or more halogen; or substituted or unsubstituted phenyl wherein said phenyl substituent is selected from halogen, nitro and C1-C4 alkyl; provided that when R3 is bromine, X is not p-toluoyl; and a process for the preparation thereof.

Abstract: Methods of performing cycloadditions are described that include (a) combining a first reactant and a second reactant in a hydrogen bonding solvent to form a reaction mixture; and (b) reacting the first reactant and the second reactant to form a cycloadduct. Methods of performing asymmetric catalytic reactions are also described that include (a) combining a first reactant, a second reactant, and a catalytic amount of a chiral hydrogen-bond donor in a solvent to form a reaction mixture; and (b) reacting the first reactant and the second reactant to form an enantiomeric excess of a reaction product. Reaction mixtures corresponding to these methods are also described.

Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).

Abstract: The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC-PUFAs, C28-C42:4, 5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor.

Abstract: A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.

Abstract: The present invention relates to compounds represented by the following Formula Ia, in which each R1-R6 can in each case be independently selected from hydrogen or hydrocarbyl (e.g., methyl); R7 is a multivalent linking group, such as L1 is a divalent linking group, such as a bond or divalent optionally substituted hydrocarbyl; each L2 independently represents a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 independently represents a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t is from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; and E can be hydrogen or optionally substituted hydrocarbyl. The present invention also relates to compositions, such as liquid crystal compositions, and articles, such as optical elements, that include the compound represented by Formula Ia.

Abstract: A polymer includes a repeating unit shown by a general formula (1). R1 represents a hydrogen atom, a methyl group, a fluorine atom, or a trifluoromethyl group. R2 represents a substituted or unsubstituted aryl group having 6 to 22 carbon atoms. Y represents a carbon atom. X represents —X1Z1X2— which is an atomic group which forms a cyclic structure including a heteroatom together with Y. Z1 represents —O—, —S—, —CO—, —COO—, —SO—, or —SO2—. Each of X1 and X2 individually represents a single bond, a methylene group, or an alkylene group having 2 to 25 carbon atoms. Each of X1 and X2 is unsubstituted or substituted with a substituent, and optionally a carbon atom included in X1 and a carbon atom included in X2 are bonded via a divalent group.

Abstract: The invention provides a liquid crystal compound that has a large negative dielectric anisotropy (??) and also has at least one of characteristics such as the stability to heat, light or the like, a high clearing point, a suitable refractive index anisotropy (?n), a large negative dielectric anisotropy (??) and an excellent compatibility with other liquid crystal compounds. An excellent effect in which especially the value of the dielectric anisotropy (??) is increased negatively is achieved by use of the compound having two moieties of 1) a tetrahydropyran ring and and thus the effect is utilized.

Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Abstract: A liquid crystal compound is provided that has excellent characteristics, such as a negatively large dielectric anisotropy. A liquid crystal composition containing the compound, and a liquid crystal display device containing the composition are also provided. A compound having the three factors, i.e., (1) a tetrahydropyran ring, (2) terminal alkenyl chain and (3) exhibits excellent characteristics including a negatively large dielectric anisotropy (??). The use of the compound having the characteristics provides an excellent liquid crystal composition and an excellent liquid crystal display device.

Abstract: The present invention relates to compounds represented by the following Formula I, in which R1-R6 can each independently be selected from hydrogen or hydrocarbyl (e.g., methyl); L1 is a divalent linking group, such as a bond or —OC(O)—R8—C(O)O—, where R8 can be divalent hydrocarbyl (e.g., —CH2CH2—); each L2 independently represents a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 independently represents a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t is from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; and E can be hydrogen or hydrocarbyl. The present invention also relates to compositions, such as liquid crystal compositions, and articles, such as optical elements, that include the compound represented by Formula I.

Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein Q, Z, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Abstract: A process for preparing compounds of the formula (I) in which R1 and R2 are as defined in the description.

Abstract: A photoresist composition includes a polymer that includes a structural unit shown by the following formula (1), and a photoacid generator. R1 in the formula (1) represents a hydrogen atom, a fluorine atom, a methyl group, or a trifluoromethyl group, Z represents a group that forms a divalent alicyclic group having 3 to 20 carbon atoms together with a carbon atom bonded to X, X represents an alkanediyl group having 1 to 6 carbon atoms, Y represents a hydrogen atom or —CR2R3(OR4), and R2 to R4 independently represent a hydrogen atom or a monovalent hydrocarbon group, provided that R3 and R4 optionally bond to each other to form a cyclic ether structure together with a carbon atom bonded to R3 and an oxygen atom bonded to R4.

Abstract: There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): wherein Ra represents an alkyl group, such as a C1-16 alkyl group, and preferably an isopropyl group; Rb represents an aryl group, preferably a 4-fluorophenyl group; Rc represents hydrogen, a protecting group or an alkyl group, such as a C1-16 alkyl group, and preferably a methyl group; and Rd represents hydrogen, a protecting group or a SO2Re group where Re is an alkyl group, such as a C1-16 alkyl group, and preferably a methyl group.

Abstract: The invention relates to the use of compounds of formula I wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention deficit disorders or Alzheimer's disease. The invention also relates to some compounds of formula I and pharmaceutical compositions containing them.

Abstract: A convenient, rapid, and highly sensitive protein detection method is provided. According to the present invention, an easily water-soluble compound of formula I is provided: [wherein, R1 and R2 are same or different, each of which is an aryl or heteroaryl group substituted with one or more anionic substituents].

Abstract: Compounds of formula (I) and pharmaceutical compositions containing them are described. The use of the compounds and compositions are also described.

Abstract: The present invention relates to alkyl-substituted tetrahydropyrans, mixtures containing these alkyl-substituted tetrahydropyrans, their respective use and corresponding flavored products.

Abstract: The present invention provides bicyclo-heptan-2-amines that selectively bind to the sigma-2 receptor and are useful in the treatment of diseases related to the sigma-2 receptor, for example, cancer and neurological disorders.

Abstract: The invention provides a liquid crystal compound having stability to heat, light and so forth, a wide temperature range of a nematic phase, a small viscosity, a suitable optical anisotropy, and a suitable elastic constant K33, and further having a suitable and negative dielectric anisotropy and an excellent compatibility with other liquid crystal compounds, and a liquid crystal composition having stability to heat, light and so forth, a low viscosity, a large optical anisotropy, a suitable and negative dielectric anisotropy, and a suitable elastic constant K33, a low threshold voltage, a high maximum temperature (phase-transition temperature on a nematic phase-isotropic phase) of a nematic phase, and a low minimum temperature of the nematic phase. The liquid crystal compound which has a specific structure having fluorine at a lateral position and also having phenylene in which hydrogen on the benzene ring is replaced by fluorine, and a liquid crystal composition containing the compound are prepared.

Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.